Related Experiment Video
Updated: Sep 29, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
An update on the clinical approach to giant cell arteritis
Rachel Piccus1, Michael Stormly Hansen2, Steffen Hamann2
1University of Birmingham Medical School, Edgbaston, UK.
Abstract:
Recent national and international guidance from rheumatology societies have reflected the advances in evidence for both the investigation and management of giant cell arteritis. Cranial ultrasound reduces diagnostic delay and improves clinical outcomes. Immediate high-dose glucocorticoids remain the standard treatment for giant cell arteritis. Randomised controlled trial evidence using tocilizumab, an interleukin-6 receptor antagonist, has been shown to have good clinical efficacy with glucocorticoid sparing effects. Overall patient outcomes appear to be improved by formalising pathways for diagnosis to include clinical experts' opinion early in decision making.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
06:53A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
Published on: July 9, 2020
Related Concept Videos
Aneurysm III: Interprofessional Care
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management
Myocarditis II: Clinical Features and Diagnostic Tests
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...